Myriad Genetics, Inc. has received United States Food and Drug Administration approval for its MyChoice CDx Test as the companion diagnostic for Zejula (niraparib), a PARP inhibitor developed by GSK, in patients with advanced ovarian cancer. The approval is supported by final data from the PRIMA trial, where the diagnostic was used to determine homologous recombination deficiency status and guide patient selection for therapy.

This regulatory milestone places Myriad Genetics, Inc. more firmly at the intersection of diagnostics and therapeutics, reinforcing the role of biomarker-driven decision-making in ovarian cancer. Rather than simply validating an existing test, the approval formalizes HRD testing as a required step in identifying patients eligible for niraparib maintenance therapy, reshaping how treatment pathways are structured in clinical practice.

How the approval strengthens HRD testing as a decision-making gatekeeper in ovarian cancer care pathways

The designation of MyChoice CDx as the companion diagnostic for niraparib elevates homologous recombination deficiency testing from a supportive biomarker to a clinical gatekeeper. Treatment eligibility is now more tightly linked to genomic profiling, making testing an essential component of care.

Clinicians tracking ovarian cancer management have increasingly recognized that a significant proportion of advanced cases may exhibit HRD-positive tumors, which are more likely to respond to PARP inhibition. However, identifying these patients consistently has remained a challenge due to variability in testing approaches. The FDA approval introduces a level of standardization that could influence how oncologists approach first-line maintenance therapy decisions.

Industry observers suggest that this shift may also reduce ambiguity in treatment selection. With a clearly defined, FDA-approved diagnostic pathway, clinicians may have greater confidence in aligning therapy with biomarker status. This could streamline decision-making in time-sensitive settings, particularly following response to platinum-based chemotherapy.

At the same time, the gatekeeping role of HRD testing introduces dependency on diagnostic availability and turnaround times. If testing delays occur, treatment initiation could be impacted, raising operational questions for oncology practices.

What this reveals about the increasing interdependence between companion diagnostics and PARP inhibitor strategies

The approval highlights how closely tied diagnostics have become to the success of targeted therapies. PARP inhibitors such as niraparib have demonstrated efficacy in biomarker-defined populations, but their real-world adoption depends on reliable identification of eligible patients.

For GSK, aligning niraparib with an FDA-approved companion diagnostic strengthens its positioning in a competitive PARP inhibitor market. Regulatory watchers suggest that a clearly defined testing pathway may support prescribing confidence and facilitate reimbursement discussions.

For Myriad Genetics, Inc., the approval represents a strategic embedding of its diagnostic platform within a therapeutic ecosystem. Each use of niraparib potentially drives demand for MyChoice CDx testing, creating a recurring linkage between drug utilization and diagnostic volume. This reflects a broader trend in precision oncology, where diagnostics are increasingly integrated into therapeutic pathways.

However, this interdependence also introduces competitive dynamics. Other diagnostics developers are likely to pursue similar approvals tied to competing PARP inhibitors, potentially leading to a fragmented landscape where different drugs require different tests.

Why the PRIMA trial linkage provides clinical credibility but does not fully resolve biomarker variability concerns

The use of MyChoice CDx in the PRIMA trial provides an important layer of clinical validation, linking the diagnostic directly to patient outcomes observed in a controlled study. This connection is likely to strengthen confidence among oncologists who prioritize evidence demonstrating clinical utility.

Clinicians evaluating diagnostic tools consider not only analytical accuracy but also whether biomarker identification translates into meaningful patient benefit. The integration of HRD testing into the trial design suggests that the diagnostic informs therapeutic outcomes rather than serving as a purely exploratory marker.

Despite this, HRD remains a complex biomarker. Regulatory watchers indicate that there is still no universal consensus on how HRD should be defined or measured. Different assays may use varying thresholds and scoring systems, leading to potential discrepancies in patient classification.

The MyChoice CDx Test incorporates multiple genomic instability measures, including BRCA1 and BRCA2 mutations alongside broader genomic signatures. While this comprehensive approach reflects current scientific understanding, it also introduces complexity that may not be easily replicated across all platforms.

How reimbursement dynamics and healthcare system constraints could shape real-world uptake of HRD testing

The commercial impact of the approval will depend on how healthcare systems and payers respond to expanded HRD testing. Companion diagnostics linked to approved therapies often benefit from clearer reimbursement pathways, but cost considerations remain central to adoption decisions.

Payers are likely to evaluate whether routine HRD testing leads to improved outcomes that justify the associated costs. Industry observers note that demonstrating more precise patient selection and avoidance of ineffective treatments could strengthen the economic case.

However, disparities in access may emerge. Large academic centers are well positioned to adopt comprehensive genomic testing, while smaller settings may face challenges related to cost and logistics. Laboratory capacity will also be critical as demand increases, since delays in testing could disrupt treatment timelines.

What risks and unresolved questions remain around long-term clinical utility and biomarker evolution

Despite the regulatory milestone, several uncertainties remain. One key question is how the role of HRD testing will evolve as new therapies and combinations enter the ovarian cancer landscape. As treatment options expand, the predictive value of HRD status may change.

Another concern is the lack of harmonization across HRD assays. Variability in scoring algorithms and thresholds could lead to inconsistent results between tests, complicating clinical decision-making. Greater standardization may be needed to ensure comparability.

The integration of HRD testing with other emerging biomarkers also presents challenges. Advances in tumor profiling, including circulating tumor DNA and broader genomic panels, could either complement or compete with existing HRD tests.

Real-world evidence will be critical in validating the impact of HRD-guided therapy outside clinical trials. While the PRIMA trial provides a strong foundation, outcomes in broader patient populations may differ due to variability in testing practices.

How Myriad Genetics could leverage this approval to expand its influence across precision oncology diagnostics

The FDA approval strengthens Myriad Genetics, Inc.’s position within precision oncology diagnostics, particularly in gynecologic cancers. By securing a central role in the niraparib treatment pathway, the diagnostics-focused company has embedded its technology into clinical workflows.

Industry observers suggest that this model could extend to other therapeutic areas as more oncology treatments require biomarker-based selection. Companies that establish early partnerships with pharmaceutical developers may gain a competitive advantage.

Maintaining leadership will require continued innovation as sequencing technology and biomarker discovery evolve. Myriad Genetics, Inc. will need to ensure that its platform adapts to changing scientific and clinical requirements.

The approval reflects a broader shift toward integrated precision medicine, where diagnostics and therapeutics are developed together. For clinicians, this offers the potential for more targeted treatments, while for healthcare systems it introduces new considerations around testing infrastructure and workflow integration.

  companion diagnostics, GSK, homologous recombination deficiency, HRD testing, MyChoice CDx Test, Myriad Genetics Inc., ovarian cancer, PARP inhibitors, PRIMA trial, Zejula niraparib